With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins and RNA/protein complexes.
Hence, as the go-to meeting for the RNA-targeting small molecule the community, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures, delve into innovative preclinical modelling strategies and identify optimal chemical features for advancing specific, efficacious and safe small molecules.
Unite with 100+ RNA Science, Medicinal Chemistry, Structural Biology & Biophysics experts from the likes of AstraZeneca, Sanofi, Novartis, PTC Therapeutics, ReviR Therapeutics, Rgenta Therapeutics, Accent Therapeutics and more at the most comprehensive and definitive event for the community, the 7th RNA-Targeted Drug Discovery & Development Summit, to accomplish faster and smoother translation of RNA targeted therapies towards the clinic.
Event link here.